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Abstract
Sentinel lymph node biopsy (SLNB) has become the standard staging technique in the surgical treatment of breast 
cancer, replacing the older method of dissecting lymph nodes of the axilla. Several advantages like lowering of 
the morbidities that accompany the technique and being less invasive have given rise to a promising effect on life 
aspects of patients suffering from this morbidity. The procedure has evolved over the last few decades, but further 
studies are still needed to make improvements. Several aspects of the evolution of SLNB, such as the incorporation 
of the management in early cancer, the technique of lymphatic mapping, the accuracy of the technique, and its utility 
and evaluation in clinical response after neoadjuvant chemotherapy are discussed in this review.
Introduction
Malignant tumor of the breast is currently 
accepted as a non-communicable disease burden 
all over the world. Data from cancer facts and 
figure 2018 [1] by the American Cancer Society reveals 
that about 1.7 million new cases will be diagnosed in 
2018. It has also become the number one estimated 
new cases of cancer in women expected to be 
266,120. The death rate in a female caused by this 
particular cancer had progressively declined year by 
year and currently stands at 14%. This achievement 
is considered an improvement attributed to early 
detection and treatment [2]. Experimental studies have 
been conducted to improve furthermore the screening 
and therapy technique of breast cancer to improve 
early detection and life aspects of patients with this 
particular disease, therefore, preventing complications 
and concomitantly elevating the 5 years survival rate.
Sentinel lymph node (SLN) is characterized by 
its properties as the foremost node by which of a lymphatic 
vessel where the above will receive the drainage of a 
specific anatomical area that has the properties of an 
immune system through which it is responsible for that 
particular area [2]. The condition of the nodes within the 
axilla is thought to be a significant predicting feature in 
the early stages of breast malignancies; thus, SLN biopsy 
(SLNB) has evolved to be the standard management 
in determining advanced metastases to the lymphatic 
node vessel. SLNB has now taken an important role 
thus has replaced axillary lymph node dissection 
(ALND) as the standard technique for staging in those 
with clinically node-negative malignancy of the breast. 
Mapping of the lymphatic nodes to reveal the sentinel 
node was achieved in 1992 using blue dye by Donald 
Morton for cutaneous melanoma. The procedure was 
initially used to discover the spread through the sentinel 
node in those suffering from melanoma in the interest 
to those which would have earned beneficial properties 
from an immediate dissection of a regional node [3]. 
Thus afterward, in 1993, Krag et al. have mapped these 
nodes by injection of a radioactive contrast utilizing 
gamma probes in the management of malignancy of the 
breast [4]. As for now, SLNB has revolutionized surgical 
treatments of early malignancy and has become the 
standard of care over axillary node dissection for staging 
grounds and or purpose in a negative node disease 
because it is precise while having a lesser extent of 
morbidity and has the properties of being non-invasive. 
Ongoing studies are currently being done to further 
explore the advantages and utility of the biopsy of the 
SLN in breast malignancies [5].
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This article is committed to reviewing the 
evolution, current status, and function of SLNB in 
malignancies of the breast.
SLN in Malignancies of the Female Breast
SLN is by definition the foremost node which 
drains a tumor which is often more than one. In breast 
cancer, the condition of the node of the axilla is currently 
known as the ultimate prognosticator of disease-free 
and overall survival rate. Furthermore, it functions as a 
guide in determining the options of local and systemic 
adjuvant treatment strategies. The involvement of the 
axillary node has already been recognized as a marker 
of bad outcome where the 5-year survival rate which will 
have been decreased by approximately 28–40% [6]. 
It should be stressed that surgery (axillary node) is 
recognized as an instrument for staging and control an 
area of a specific region to maximize the survival rate 
in these patients. To establish a definitive diagnosis of 
axillary metastasis, this will further require excision and 
histological examination of axillary lymph nodes.
The thorough processes taken in the evaluation 
of axillary node conditions involves the routine application 
of surgical staging where tissues (lymph) were removed 
between the vein of the axilla in the superior area, the 
muscle of the serratus anterior in the medial area, and 
the muscle of the latissimus dorsi within the lateral area. 
In the management of breast cancer ALND is currently 
well known as the ultimate standard (gold standard) for 
staging. It is accurate and sensitive but on the other 
hand, still has the downside of higher morbidities like 
longer operating time, pathology costs and several 
complications known for effects of formation of seroma, 
axilla sensory deprivation, edema of the arm and 
limitation of movement. Thus it renders a dilemmatic 
condition especially in those whose nodes are clinically 
negative, i.e., cN0 because most of them will have a 
pathological free node (pN0) and will be more exposed 
to invasive surgery, which leads to the development of 
higher morbidity outcome. All of the above mentioned 
will affect the quality of life in these patients for axillary 
control and survival which remain questionable. For this 
reason, several studies have been done to explore a 
less invasive tool for staging females with breast cancer.
After the introduction of SLNB, the morbidity 
for pN0 patients has been dramatically reduced. The 
results of the study Z0011 show that there was no 
differentiation between patients undergoing SLNB and 
axillary dissection after 10 years [7]. However, some 
considerations will have to be made by surgeons in pN+ 
patients, whether opting for ALND, which stands by the 
guideline [8] or removal of the SLN.
The total lymph nodes to be removed will vary 
from patient to patient. In general, ALND is defined 
as the removal of 10 or more nodes. The German S3 
guideline states that ten nodes are the lowest amount to 
take out for the pathological report [8]. Recent studies 
show that there is no survival benefit of the procedure 
because the removal of fewer than 4 nodes can already 
be used for an accurate diagnosis [9].
The Evolution of SLNB
The SLNB has been accepted and well known 
of its feature of less invasive alternative and has now 
replaced the full ALND for those who underwent primary 
breast operation in cN0 and in the early stages of breast 
malignancies before breast-conserving management.
The foremost SLNB was performed in 1951 by 
Gould [10] during parotidectomy, and further technique 
was adopted for other diseases by Cabanas [11] in 
penile cancer and by Morton et al. [12] in a patient 
with cutaneous melanoma. By the next few years, this 
technique was adopted in the management of breast 
cancer in 1994 by Guliano et al. [13] at John Wayne 
Cancer Institute. It was known for their ability to identify 
the status of the nodes in the range of 95% compared 
with the dissection of the axilla by use of blue dye. 
This study further shows that it is attainable to identify 
sentinel node in breast malignancies and it is capable 
to accurately foresee the condition of the entire axillary 
vessel. Different SLNB injection technique was done by 
Krag et al. [5] by utilizing radioisotopes in conjunction 
with the gamma probe localization.
Several studies compared ALND and SLNB 
to evaluate the sensitivity of detection rate and post-
operative morbidity. Data have shown that there 
was less morbidity of the arm and shoulders such 
as edema, sensory, and mobility deprivation after 
SLNB compared to ALND which correlates with a 
higher quality of life. NSABP B-32 is well known as 
the largest trial to evaluate sentinel node biopsy and 
has conceded that disease-free survival, regional 
control, and total survival were equivalent between 
sentinel node biopsy only group and combination of 
sentinel node biopsy in addition to the dissection of 
the axilla group [14]. A randomized clinical trial by 
The ACOSOG Z0011 (Alliance) aimed to evaluate 
the outcome of the dissection of the axilla versus no 
dissection on 10 years overall survival in those with 
invasive malignancies of the breast and SN metastasis 
which has stated that SLN dissection only was not 
inferior to overall survival compared to patients that 
had been managed by dissection of nodes within the 
axilla [7]. At present, SLNB evolved to be the merit of 
care for the management (surgery) and evaluation of 
malignancies of the breast because of its accuracy, 
limited morbidities while also has the properties of 
limiting an invasive operation.
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Figures of Sentinel Nodes Identified in 
Malignancies
The SLNs are characterized because of its 
properties to be one of the first to receive drainage from 
a malignant growth bed. In the axillary bed, there could 
be more than one of these detected. The question was 
how many SLNs are necessary to take out for it to 
attain a tolerable accuracy rate in addition to low false-
negative rate (FNR) since those numbers are related 
to complications of the axilla which contributes to 
further morbidity. Several studies have suggested the 
number of SLN’s that should be removed in SLNB to 
yield a low FNR and that four nodes were considered 
an acceptable threshold number and removal of more 
SLNs will not yield higher staging accuracy [9].
A prospective multicenter study at the 
University of Louisville was conducted by Anees 
et al. [15] to evaluate determining elements which are 
correlated to the harvest of SLN. This was based on 
the proposition that taking out of more than four nodes 
will have elevated the quality of being unhealthful 
without increasing staging precision nor advantage 
over complete dissection of the axilla. Samples were 
relatively large with 3882 subjects over 8-year period. 
Three hundred and thirty-six surgeons had done the 
procedures without any definitive protocol to do SLN 
biopsy. Tangible tumor, the familiarity of the surgeon, 
and injection technique were related to the amount 
of (number) “sentinel lymph nodes” taken out and 
less than four SLNs were considered adequate for a 
diagnostic tool. Another substantial study measured 
the number of SLNs taken to see the relation of 
disease (specific) survival and results showed positive 
results in those that had three SLNs taken out having 
better outcomes. It will become understaging if only 
one or two SLNs were taken. This study showed no 
remarkable benefit in survival for those with SLNB only 
compared to SLNB followed by ALND treatment. The 
only additional information retrieved was the number of 
nodes containing metastases, while, on the other hand, 
this prognostic data would not have change systemic 
therapy decisions and will further result in a significantly 
higher cost [16].
From several data and literature, the authors 
conclude that the removal of four nodes should be 
sufficient and overall data suggest that this concept will 
have higher accuracy and lower FNR.
SLNB Technique
In malignancy, SLN is generally found under the 
arm with a relatively small proportion found elsewhere in 
the lymphatic system (breast). If the SLN is affirmative, 
possibilities of a positive node upstream could be 
expected, whereas a negative SLN shows that the high 
probability of all upstream nodes is of the same. SLN 
biopsy is done by locating the and thus identifying it utilizing 
a (labeling) substance by an option of a radiotracer, blue 
pigment(dye) or in combination, which is administered 
around the tumor before mastectomy or lumpectomy. 
This marker will then travel to the same track of the nodes 
that malignant cells would manifest, rendering surgeons 
to decide the one or two nodes have the most probability 
to be positive, either evaluating it using color visualization 
or Geiger counter. Injection techniques differ between 
institutions, surgeon preferences, and skills [13], [17].
There are currently three common mapping 
schemes incorporating variable tracers SLNB through 
the utilization of radioisotope, blue coloring, and the 
combination of both [5], [18]. Surgeons will have to 
individualize their preferences to suit their practice. Some 
literature reveals the identification rate can be optimized 
while minimizing FNR by incorporating dual agents, 
especially for those with limited experience and in such 
instances where misidentification and false-negative rates 
are known to be higher. Several conditions which have 
shown to have higher FNR were prior breast surgery, 
neoadjuvant chemotherapy, and high BMI index [17], [19].
The current benchmark (gold standard) for 
SLNB is a dual-modality technique (radioisotope and 
blue coloring). The technique incorporates administration 
of a technetium-labeled nanocolloid and blue coloring 
interstitially into the breast on all sides of the tumor or 
periareolar region. After localizing itself in the lymphatic 
network, a scintillation counter is utilized to determine 
SLN which accepts the chief drainage from the tumor 
through a lymphatic network (vessel). The blue coloring 
will assist with localization after incision and nodes that 
are blue, radioactive, or both are recognized as SLN, 
thus taken out and examined [20], [21].
Despite low false-negative and high detection 
rate, this method has several disadvantages of using 
technetium 99 which has only 6 h of half-life, therefore, 
restricting scheduling of surgery. The limitation of 
the combined SLNB and allergic reaction paved 
the way for the evolution of another method. Recent 
studies have focused on the use of indocyanine green 
fluorescence and contrast-enhanced ultrasound 
(CEUS) using microbubbles or superparamagnetic 
iron oxide nanoparticles, but data and studies are 
currently inconclusive regarding the identification of 
any significant benefit of the previous dual technique in 
terms of SLN detection rate [22], [23].
SLNB after Neoadjuvant Chemotherapy
Neoadjuvant chemotherapy was at first 
introduced to locally downstage advanced malignancies 
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to ease surgery which will result in the improvement 
of disease-free and increasing survival rate in a 
considerable percentage (20–40) of patients [24]. NAC 
nowadays is also used as initial therapy for early breast 
malignancies before breast preserving surgeries. 
Before NAC node-staging was done by dissection of 
the axillary lymph nodes during breast operations 
which were correlated with higher morbidity. SLNB is 
by definition a less aggressive approach to determine 
nodal staging and results in lesser morbidities. SLNB 
before NAC can precisely assess initial node condition 
circumventing the side effect of lymphatic scarring 
or uneven node tumor response but become more 
challenging than SLNB after NAC as an appealing 
approach as NAC could downstage node conditions in 
several patients. Otherwise, this will become important 
to show recurrence rate and to set up for further therapy. 
Before such strategies may be offered as routine 
several questions need to be answered in accordance 
to its safety validity, predictive value, and optimal timing 
of SLNB before NAC [25].
Several studies have been performed to 
determine sentinel biopsy before and after NAC. 
The advantage of performing sentinel node biopsy 
before giving neoadjuvant chemotherapy lies in the 
predetermination of nodal status which will ultimately 
affect the next regiment that the patient will receive 
depending on tumor size and biopsy result. This method 
will not further force the patient to further surgeries and 
may delay the timing of chemotherapy, thus presenting 
the most precise regional-staging for them [26].
Varying literature reveals that NAC may 
exhibit a number of unwanted effects on the accuracy 
of SLNB. The primary tumors and metastatic nodes 
which respond to chemotherapy produce reactive 
changes such as fibrosis that can influence drainage 
patterns. Irregular response in the elimination of axillary 
nodes which in turn may result in decreased sentinel 
node accuracy after NAC [25]. Several studies which 
registered patients with an SLNB biopsy before (1st) and 
after (2nd) NAC group revealed a significantly decreased 
SLN identification in the second group.
A prospective, multicenter cohort study had 
been conducted by Kuehn et al. [26] took place at 103 
institutions in Germany and Austria. The (SENTinel 
NeoAdjuvant) study was aimed to assess an algorithm 
for the timing of a standardized SLNB in those who 
underwent NAC. The key endpoint of the study was 
the accuracy of SLNB after NAC, secondary endpoints 
is a comparison of the detection rate of SLNB before 
and after NAC, and also the FNR and detection rate of 
SNLB after taking out the SLN. In conclusion, SLNB is 
a well-founded diagnostic method before NAC, but this 
procedure has a lower detection rate and a higher FNR 
compared with SLNs performed before NAC.
Another multicenter prospective study 
was performed by Enokido et al. at eight centers in 
Japan [27]. This study, with a sample of 143 patients with 
breast malignancies with positive axillary nodes proven 
by FNAB cytology at the initial diagnosis (T1-T3N1M0), 
was done to determine the suitability of SLNB for 
patients with node-positive breast malignancies before 
NAC. In this study, SLNB was done by blue coloring 
and radiolabeled colloid agents to optimize the chance 
of SLN identification. In conclusion, the study of breast 
cancer patients who had ALN conversion from cytology-
determined positive to negative following NAC indicated 
that SLNB and ALND without SLNB had similar rates of 
axillary recurrence, disease-free survival, and overall 
survival. Therefore, SLNB may be acceptable after NAC 
for patients with cytology determined, node-metastasis-
positive breast cancer with a reasonable identification 
rate. Furthermore, in some patients, SLNB can help 
identify possible downstaging to a negative nodal 
stage, and since ALND is avoided, this may reduce 
arm motion morbidity and lymphedema. We suggest 
the use of SLN surgery as an alternative to ALND after 
NAC in patients with cytology determined axillary node 
metastasis positive breast cancer [27].
 There were also several factors which 
contribute to sentinel node identification rate and false-
negative rate after neoadjuvant chemotherapy. Several 
studies point to have a low detection rate and a high 
FNR. Initial reports from a single institution showed 
inconsistency in sentinel node identification rates 
after neoadjuvant chemotherapy from 72% to 100% 
and FNRs of 0–33% [28]. The Ganglion sentinelle et 
chimiotherapie neoadjuvante study was a prospective 
study with conservative breast surgery, sentinel 
biopsy, and level I and II axillary lymphadenectomy 
after NAC for large operable breast malignancies [29]. 
This study was conducted from September 2003 until 
March 2007, with a total of 195 subjects prospectively 
included from 12 institutions. The study showed that 
the detection rate was 90%, the FNR 11.5% and that 
subjects with no palpable axillary nodes (N0) before 
NAC had a better detection rate compared to patients 
with axillary suspicious nodes. This study finally 
concluded the practicality of sentinel node biopsy after 
neoadjuvant chemotherapy in cases of extensive breast 
malignancies [28].
Due to the lack of sufficient data available 
currently to endorse NAC as a standard procedure, there 
is a prospective role for SLNB following neoadjuvant 
chemotherapy on an individual basis.
Conclusion
SLNB nowadays has been recommended as 
a preferable treatment to ALND and also to avoid the 
use of ALND in a clinically negative axillary node. Three 
factors that will determine the ability to identify SLN are 
tumor palpability, surgeon’s experience, and the biopsy 
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technique. The tendencies of a nonpalpable tumor are 
greater toward the failure of identifying SLN; thus, in 
these cases, the dual-injection technique (with blue 
dye and radiocolloid) should be recommended. Despite 
the limitations of the dual technique in SLNB, further 
studies are currently being conducted to find a more 
effective method to detect the sentinel node.
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